A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended
dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3804 in
patients with advanced malignant tumors.